GSK (GSK) announced that the China National Medical Products Administration has approved Nucala, a monoclonal antibody that ...

GSK (NYSE:GSK) has received Chinese regulatory approval for its drug Nucala, also known as mepolizumab, for the treatment of ...

GlaxoSmithKline ( (GSK) ) has provided an update. GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with ...

On Friday, the China National Medical Products Administration approved GSK plc (NYSE:GSK) Nucala (mepolizumab) as an add-on ...

GSK receives China NMPA approval for Nucala to treat adults with chronic rhinosinusitis with nasal polyps: London, UK Saturday, January 4, 2025, 09:00 Hrs [IST] GSK plc announced ...

London: GSK plc has announced that the China National Medical Products Administration has approved Nucala (mepolizumab), a ...

China’s National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody from UK ...

GSK announced on Friday that its monoclonal antibody ‘Nucala’, or mepolizumab, has received approval from China's National ...

GlaxoSmithKline (GSK) is on course for US approval of its mepolizumab candidate after an FDA advisory committee voted unanimously in favour of its use in adults with severe asthma.

Mepolizumab is a monoclonal antibody that targets ... 390 million people globally and over 14 million people in the US. GSK noted that recurrent exacerbations add to pressures on healthcare ...

(Alliance News) - GSK PLC on Friday reported that its Nucala treatment has been approved in China to treat long-term sufferers of a sinus ailment following a phase 3 study.